Palabras clave
Ultrasonidos focalizados
Neuroinflamación
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Evaluar el impacto de la modulación de la barrera hematoencefálica mediante ultrasonidos focalizados en la neuroinflamación, con especial atención a las implicaciones terapéuticas para las enfermedades neurológicas y neurodegenerativas. Metodos: Revisión integradora en PubMed Central (PMC). Se seleccionaron inicialmente 587 artículos. En base a estrictos criterios de inclusión y exclusión, utilizando únicamente artículos en inglés entre 2020 y 2024, se seleccionaron 17 artículos. Resultados: El uso de ultrasonido focalizado influye directamente en los procesos neuroinflamatorios, al inducir la apertura temporal de la barrera hematoencefálica, promoviendo el efecto de mayor penetración de terapias inmunológicas y farmacológicas, así como el proceso depurativo de proteínas con estimulación celular y neurogénica, permitiendo también la mejoría cognitiva, sin daño o muerte celular asociada. Consideraciones finales: El ultrasonido focalizado es un enfoque prometedor y sencillo, que permite su uso en procesos neurodegenerativos, neuroinflamatorios, neurooncológicos y trastornos neuromotores. Sin embargo, deben realizarse más estudios para demostrar el máximo potencial terapéutico de esta categoría terapéutica.
Referencias
BATHINI e PRAVEEN, et al. Acute effects of focused ultrasound-induced blood-brain barrier opening on anti-pyroglu3 abeta antibody delivery and immune responses. Biomolecules, 2022; 12(7): 951.
CHANG WLK, et al. Rapid short‐pulses of focused ultrasound and microbubbles deliver a range of agent sizes to the brain. Science Reports, 2023; 13: 6963.
CHAVES JCS, et al. Alzheimer's disease brain endothelial-like cells reveal differential drug transporter expression and modulation by potentially therapeutic focused ultrasound. Neurotherapeutics, 2024; 21(1): 299.
CHOI HJ, et al. The new insight into the inflammatory response following focused ultrasound-mediated blood–brain barrier disruption. Fluids and Barriers of the CNS, 2022; 19: 103.
DENG Z, et al. Ultrasound-Induced Blood-Brain-Barrier Opening Enhances Anticancer Efficacy in the Treatment of Glioblastoma: Current Status and Future Prospects. Journal of Oncology, 2019; 1: 2345203.
DUBEY S, et al. Clinically approved IVIg delivered to the hippocampus with focused ultrasound promotes neurogenesis in a model of Alzheimer’s disease. Proceedings of the National Academy of Sciences, 2020; 117(51): 32691–32700.
FISHER DG e PRICE RJ. Recent Advances in the Use of Focused Ultrasound for Magnetic Resonance Image-Guided Therapeutic Nanoparticle Delivery to the Central Nervous System. Frontiers in Pharmacology, 2019; 10: 1348.
FISHMAN OS e FISCHELL JM. Focused ultrasound mediated opening of the blood-brain barrier for neurodegenerative diseases. Frontiers in Neurology, 2021; 12: 74904.
HAROON J, et al. Use of transcranial low-intensity focused ultrasound for targeted delivery of stem cell-derived exosomes to the brain. Scientific reports,2023; 13(1): 17707.
JEONG H, et al. A pilot clinical study of low-intensity transcranial focused ultrasound in Alzheimer’s disease. Ultrasonography, 2021; 40(4): 512-519.
KONG C e CHANG WS. Preclinical Research on Ultrasound-Mediated Blood-Brain Barrier Opening for Neurological Disorders: A Review. Neurology International, 2023; 15(1): 285-300.
LAPIN NA, et al. Consistent opening of the blood brain barrier using focused ultrasound with constant intravenous infusion of microbubble agent. Scientific reports, 2020;10(1): 16546.
LEONOR K, et al. Transcranial short study of the focused clinical utrassound in the blood brain barrier. Nature in Neuroscience, 2020; 12(2): 250.
MCMAHON D, et al. Therapeutic Agent Delivery Across the Blood–Brain Barrier Using Focused Ultrasound. Annual Reviews, 2021; 23: 89-113.
PROFACI CP, et al. The blood–brain barrier in health and disease: Important unanswered questions. Journal of Experimental Medicine, 2020; 217: 20190062.
REZAI AR, et al. Focused ultrasound–mediated blood-brain barrier opening in Alzheimer’s disease: long-term safety, imaging, and cognitive outcomes. Journal of Neurosurgery, 2023; 139(11): 1-275–283.
RIGOLLET S, et al. FUS-mediated BBB opening leads to transient perfusion decrease and inflammation without acute or chronic brain lesion. Theranostics, 2024; 14(10): 4147-4160.
SCOTT K e KLAUS SP. Focused ultrasound therapy for Alzheimer’s disease: exploring the potential for targeted amyloid disaggregation. Frontiers in Neurology, 2024; 15(6).
SHEYBANI ND, et al. ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma. Journal of controlled release: official journal of the Controlled Release Society, 2021; 331: 19-29.
SPIVAK NM, et al. Histological examination of focused ultrasound effects on human brain tissue. Brain Stimulation, 2021; 14: 1486-1488.
STEFANI A, et al. Neurotrophins as Therapeutic Agents for Parkinson’s Disease; New Chances From Focused Ultrasound? Frontiers in Neuroscience, 2022; 16: 846681.
THOMBRE R, et al. Towards standardization of the parameters for opening the blood–brain barrier with focused ultrasound to treat glioblastoma multiforme: A systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models. Frontiers in Oncology, 2023; 12: 1072780.
ZHAN W. Effects of focused-ultrasound-and-microbubble-induced blood-brain barrier disruption on drug transport under liposome-mediated delivery in brain tumour: A pilot numerical simulation study. Pharmaceutics 2020; 12(1): 69.